Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly, Novartis, Jazz and Ionis Take New Products To EMA

Executive Summary

Lilly’s migraine prevention therapy, galcanezumab, is among the nine new products that companies have submitted to the European Medicines Agency for evaluation in recent weeks.

Advertisement

Related Content

EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
Capacity Shortages Unlikely To Hold Back Cell And Gene Therapies
FDA's NDA And BLA Approvals: Lonhala Magnair, Ozempic
Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern
Novartis Seeks EU Accelerated Review For CAR-T Therapy
Roche Fails Again To Convince CHMP On Ocrevus, Only Teva Gets A Thumbs Up
Ten Approvals To Look Out For In Q4
Half Of All EU Fast-Track Requests Fail; AZ’s Imfinzi Among Latest
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel